Industry Newsoncologyclinical trialsbiopharmadividends
Bristol-Myers Squibb Expands ADEPT-2 Enrollment, Reports Growth
5.0
On December 4, Bristol-Myers Squibb said it will expand enrollment in the ADEPT-2 Cobenfy trial after a Data Monitoring Committee recommendation, and Leerink analyst David Risinger maintained an Outperform rating. In Q3 2025, its growth portfolio revenue rose 18% to $6.9 billion, lifting total revenue to $12.2 billion; however, a roughly 80% payout ratio raises questions about dividend sustainability despite $15.3 billion trailing free cash flow.
Key Points
- 1Expands ADEPT-2 enrollment after Data Monitoring Committee recommendation for Cobenfy Alzheimer’s psychosis trial.
- 2Reports 18% growth in Q3 2025 growth portfolio to $6.9 billion, driving total revenue to $12.2 billion.
- 3Indicates strong oncology momentum but an ~80% payout ratio pressures dividend sustainability for income investors.
Scoring Rationale
Company-reported growth and trial expansion support relevance, but limited broader impact and no AI/ML significance.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems
